Josh Osowicki
@joshosowicki.bsky.social
Reposted by Josh Osowicki
How can we accelerate human trials of vaccines, therapeutics and diagnostics against priority pathogens in advance of epidemics and pandemics? Well, if we can identify safe, weakened versions controlled human infection model trials might be possible:
journals.plos.org/plosntds/art...
🧪 🩺 #IDsky
journals.plos.org/plosntds/art...
🧪 🩺 #IDsky
Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review
Author summary There are several families of viruses that scientists predict are most likely to cause a future pandemic, such as coronaviruses or Ebola. Studying these viruses ahead of time might mean...
journals.plos.org
January 3, 2026 at 8:50 AM
How can we accelerate human trials of vaccines, therapeutics and diagnostics against priority pathogens in advance of epidemics and pandemics? Well, if we can identify safe, weakened versions controlled human infection model trials might be possible:
journals.plos.org/plosntds/art...
🧪 🩺 #IDsky
journals.plos.org/plosntds/art...
🧪 🩺 #IDsky
Reposted by Josh Osowicki
1/2
Progress in vaccine development only happens when people are willing to step up. Challenge trials are one of the most powerful tools we have for speeding lifesaving vaccines. If we want faster, more equitable global health outcomes, we need to expand and support this research model.
Progress in vaccine development only happens when people are willing to step up. Challenge trials are one of the most powerful tools we have for speeding lifesaving vaccines. If we want faster, more equitable global health outcomes, we need to expand and support this research model.
December 15, 2025 at 8:45 PM
1/2
Progress in vaccine development only happens when people are willing to step up. Challenge trials are one of the most powerful tools we have for speeding lifesaving vaccines. If we want faster, more equitable global health outcomes, we need to expand and support this research model.
Progress in vaccine development only happens when people are willing to step up. Challenge trials are one of the most powerful tools we have for speeding lifesaving vaccines. If we want faster, more equitable global health outcomes, we need to expand and support this research model.
Reposted by Josh Osowicki
Congratulations to Burrell St Sexual Health: First UK patient into SOS Global - Evaluating mucosal shedding of spirochetes in heterosexual individuals with syphilis.
Great collaboration led by Melbourne Sexual Health Centre focused on understanding syphilis transmission.
Great collaboration led by Melbourne Sexual Health Centre focused on understanding syphilis transmission.
December 2, 2025 at 11:38 AM
Congratulations to Burrell St Sexual Health: First UK patient into SOS Global - Evaluating mucosal shedding of spirochetes in heterosexual individuals with syphilis.
Great collaboration led by Melbourne Sexual Health Centre focused on understanding syphilis transmission.
Great collaboration led by Melbourne Sexual Health Centre focused on understanding syphilis transmission.
Reposted by Josh Osowicki
In a trial in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, two doses of the candidate vaccine CVD 1902 led to protection against S. Paratyphi A infection. Full VASP phase 2b trial results: nej.md/3Lypfd5
#MedSky #IDSky
#MedSky #IDSky
October 31, 2025 at 1:02 PM
In a trial in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, two doses of the candidate vaccine CVD 1902 led to protection against S. Paratyphi A infection. Full VASP phase 2b trial results: nej.md/3Lypfd5
#MedSky #IDSky
#MedSky #IDSky
Reposted by Josh Osowicki
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
We are looking for candidates for a new fully-funded joint PhD position at the Universities of Toronto and Melbourne, working on RCTs in bloodstream infection (BALANCE+, SNAP, STRAP).
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
forms.gle
October 27, 2025 at 9:28 AM
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
Reposted by Josh Osowicki
AAMRI is thrilled to announce our 2025 AAMRI Rising Star Award Finalists, proudly sponsored by CSL.
These outstanding researchers are shaping the future of health + medical research in Australia 👏 #2025AAMRIRisingStar
aamri.org.au/news-events/...
Winner announced 4 Nov at #2025AAMRIConvention
These outstanding researchers are shaping the future of health + medical research in Australia 👏 #2025AAMRIRisingStar
aamri.org.au/news-events/...
Winner announced 4 Nov at #2025AAMRIConvention
AAMRI announces 2025 Rising Star finalists showcasing our brightest young researchers - AAMRI
AAMRI is delighted to announce the finalists for the 2025 AAMRI Rising Star Award, proudly sponsored by CSL. The award shines a spotlight on the extraordinary talent driving the future of health and m...
aamri.org.au
October 15, 2025 at 4:38 AM
AAMRI is thrilled to announce our 2025 AAMRI Rising Star Award Finalists, proudly sponsored by CSL.
These outstanding researchers are shaping the future of health + medical research in Australia 👏 #2025AAMRIRisingStar
aamri.org.au/news-events/...
Winner announced 4 Nov at #2025AAMRIConvention
These outstanding researchers are shaping the future of health + medical research in Australia 👏 #2025AAMRIRisingStar
aamri.org.au/news-events/...
Winner announced 4 Nov at #2025AAMRIConvention
Reposted by Josh Osowicki
I am exciting to publish our validated, lab-based model of oral gonorrhoea infection! With this model we can begin to understand how gonorrhoea behaves in the mouth (which is lacking) and screen for new compounds for interventions such as a gum to prevent infections. sti.bmj.com/content/earl...
sti.bmj.com
October 6, 2025 at 2:27 AM
I am exciting to publish our validated, lab-based model of oral gonorrhoea infection! With this model we can begin to understand how gonorrhoea behaves in the mouth (which is lacking) and screen for new compounds for interventions such as a gum to prevent infections. sti.bmj.com/content/earl...
Reposted by Josh Osowicki
Our new review “𝘛𝘩𝘦 𝘊𝘦𝘯𝘵𝘳𝘢𝘭 𝘐𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘤𝘦 𝘰𝘧 𝘝𝘢𝘤𝘤𝘪𝘯𝘦𝘴 𝘵𝘰 𝘔𝘪𝘵𝘪𝘨𝘢𝘵𝘦 𝘵𝘩𝘦 𝘛𝘩𝘳𝘦𝘢𝘵 𝘰𝘧 𝘈𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤-𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘉𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯𝘴” is out
Compared to antibiotics, vaccines:
✓ Act prophylactically at low pathogen burden
✓ Less prone to inducing resistance due to multifactorial nature of immune pressure
🧵1/3
Compared to antibiotics, vaccines:
✓ Act prophylactically at low pathogen burden
✓ Less prone to inducing resistance due to multifactorial nature of immune pressure
🧵1/3
August 23, 2025 at 12:00 PM
Our new review “𝘛𝘩𝘦 𝘊𝘦𝘯𝘵𝘳𝘢𝘭 𝘐𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘤𝘦 𝘰𝘧 𝘝𝘢𝘤𝘤𝘪𝘯𝘦𝘴 𝘵𝘰 𝘔𝘪𝘵𝘪𝘨𝘢𝘵𝘦 𝘵𝘩𝘦 𝘛𝘩𝘳𝘦𝘢𝘵 𝘰𝘧 𝘈𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤-𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘉𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯𝘴” is out
Compared to antibiotics, vaccines:
✓ Act prophylactically at low pathogen burden
✓ Less prone to inducing resistance due to multifactorial nature of immune pressure
🧵1/3
Compared to antibiotics, vaccines:
✓ Act prophylactically at low pathogen burden
✓ Less prone to inducing resistance due to multifactorial nature of immune pressure
🧵1/3
Reposted by Josh Osowicki
Exited to announce 2 EDCTP consortiums led @lshtm.bsky.social w partners in Europe & West, East & Southern Africa
MAMS4CL will deliver seamless Phase 2-3 trial of treatments for Cutaneous Leishmaniasis.
IVMKIDS will provide data on paediatric dosing ivermectin down to 5kg/weight for STH & Scabies.
MAMS4CL will deliver seamless Phase 2-3 trial of treatments for Cutaneous Leishmaniasis.
IVMKIDS will provide data on paediatric dosing ivermectin down to 5kg/weight for STH & Scabies.
August 21, 2025 at 8:28 AM
Exited to announce 2 EDCTP consortiums led @lshtm.bsky.social w partners in Europe & West, East & Southern Africa
MAMS4CL will deliver seamless Phase 2-3 trial of treatments for Cutaneous Leishmaniasis.
IVMKIDS will provide data on paediatric dosing ivermectin down to 5kg/weight for STH & Scabies.
MAMS4CL will deliver seamless Phase 2-3 trial of treatments for Cutaneous Leishmaniasis.
IVMKIDS will provide data on paediatric dosing ivermectin down to 5kg/weight for STH & Scabies.
Reposted by Josh Osowicki
Phenomenal piece of work by a great team across @mrcunitgambia.bsky.social @lshtm.bsky.social @sheffielduni.bsky.social - Delighted to have played a small part in combining epidemiology & immunology to shed light on what protection for #StrepA might look like & help advance vaccine development.
🧵 Our paper out today in @naturemedicine.bsky.social
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com
August 8, 2025 at 3:28 PM
Phenomenal piece of work by a great team across @mrcunitgambia.bsky.social @lshtm.bsky.social @sheffielduni.bsky.social - Delighted to have played a small part in combining epidemiology & immunology to shed light on what protection for #StrepA might look like & help advance vaccine development.
Reposted by Josh Osowicki
Fantastic to see this immense body of excellent work published! Well done @alexjkeeley.bsky.social and everyone involved 👏
#StrepA
@floreyinstitute.bsky.social
@molmicrosheffield.bsky.social
#StrepA
@floreyinstitute.bsky.social
@molmicrosheffield.bsky.social
🧵 Our paper out today in @naturemedicine.bsky.social
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com
August 8, 2025 at 10:25 AM
Fantastic to see this immense body of excellent work published! Well done @alexjkeeley.bsky.social and everyone involved 👏
#StrepA
@floreyinstitute.bsky.social
@molmicrosheffield.bsky.social
#StrepA
@floreyinstitute.bsky.social
@molmicrosheffield.bsky.social
Reposted by Josh Osowicki
VERY excited by our latest work on StrepA below, but also rhe multiple collaborations and work to come off the back of this at MRCG
🧵 Our paper out today in @naturemedicine.bsky.social
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com
August 8, 2025 at 9:14 AM
VERY excited by our latest work on StrepA below, but also rhe multiple collaborations and work to come off the back of this at MRCG
Reposted by Josh Osowicki
🧵 Our paper out today in @naturemedicine.bsky.social
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com
August 8, 2025 at 9:09 AM
🧵 Our paper out today in @naturemedicine.bsky.social
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
Reposted by Josh Osowicki
A real pleasure to be a part of this beautiful new study on T cell responses in repeat controlled human infection vs natural infection with #schistosomes, spearheaded by @emmahoulder.bsky.social with many wonderful colleagues #helminths #ImmunoSky #IDSky 🪱 🧪 www.nature.com/articles/s41...
T cell responses in repeated controlled human schistosome infection compared to natural exposure - Nature Communications
In schistosomiasis-endemic regions, the cyclical nature of infection and treatment complicates understanding of host immune responses. Repeated controlled human Schistosoma mansoni infection, designed...
www.nature.com
July 28, 2025 at 11:30 AM
A real pleasure to be a part of this beautiful new study on T cell responses in repeat controlled human infection vs natural infection with #schistosomes, spearheaded by @emmahoulder.bsky.social with many wonderful colleagues #helminths #ImmunoSky #IDSky 🪱 🧪 www.nature.com/articles/s41...
Reposted by Josh Osowicki
Congratulations to 𝐃𝐎𝐂𝐓𝐎𝐑 𝐃𝐀𝐍𝐈𝐄𝐋 𝐒𝐔𝐍 on the successful defense of his PhD "𝘊𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘪𝘯𝘨 𝘵𝘩𝘦 𝘏𝘰𝘴𝘵-𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯 𝘐𝘯𝘵𝘦𝘳𝘧𝘢𝘤𝘦 𝘧𝘰𝘳 𝘕𝘰𝘷𝘦𝘭 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘵𝘰 𝘛𝘳𝘦𝘢𝘵 𝘋𝘳𝘶𝘨 𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴" in the Biomedical Sciences Graduate Program as part of his dual degree training in the UCSD SSPPS PharmD/PhD Program
July 26, 2025 at 10:48 PM
Congratulations to 𝐃𝐎𝐂𝐓𝐎𝐑 𝐃𝐀𝐍𝐈𝐄𝐋 𝐒𝐔𝐍 on the successful defense of his PhD "𝘊𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘪𝘯𝘨 𝘵𝘩𝘦 𝘏𝘰𝘴𝘵-𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯 𝘐𝘯𝘵𝘦𝘳𝘧𝘢𝘤𝘦 𝘧𝘰𝘳 𝘕𝘰𝘷𝘦𝘭 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘵𝘰 𝘛𝘳𝘦𝘢𝘵 𝘋𝘳𝘶𝘨 𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴" in the Biomedical Sciences Graduate Program as part of his dual degree training in the UCSD SSPPS PharmD/PhD Program
Reposted by Josh Osowicki
Thanks for the reference! And of course there's this classic from @tonybreu.bsky.social x.com/tony_breu/st...
Tony Breu on X: "1/ Why hasn't syphilis developed resistance to penicillin (PCN)? It took staph aureus about a year to demonstrate resistance. After 75 years, there has never been a reported case of treponema pallidum resistant to PCN. Let’s have a look at why this might be..." / X
1/ Why hasn't syphilis developed resistance to penicillin (PCN)? It took staph aureus about a year to demonstrate resistance. After 75 years, there has never been a reported case of treponema pallidum resistant to PCN. Let’s have a look at why this might be...
x.com
July 18, 2025 at 11:50 AM
Thanks for the reference! And of course there's this classic from @tonybreu.bsky.social x.com/tony_breu/st...
Reposted by Josh Osowicki
Latest from @mrcunitgambia.bsky.social #StrepA group. Show clinical decision rules developed elsewhere (mostly HIC) have poor performance in Gambia & molecular tests detect far more #StrepA than culture. Given burden of RhD in Africa we urgently need better & affordable tests for #StrepA diagnosis
Evaluating clinical decision rules and rapid diagnostic tests for the diagnosis of Streptococcus pyogenes pharyngitis in Gambian children: a diagnostic accuracy study
Accurate diagnosis of Streptococcus pyogenes (S. pyogenes) pharyngitis is imperative
in high rheumatic heart disease-burden countries. We aimed to assess the diagnostic
accuracy of two rapid diagnosti...
www.journalofinfection.com
July 6, 2025 at 1:00 PM
Latest from @mrcunitgambia.bsky.social #StrepA group. Show clinical decision rules developed elsewhere (mostly HIC) have poor performance in Gambia & molecular tests detect far more #StrepA than culture. Given burden of RhD in Africa we urgently need better & affordable tests for #StrepA diagnosis
Reposted by Josh Osowicki
RSV and pneumococcus demonstrate close interaction in epidemiological studies but which is 🐥 and which is 🥚. This study by our group is designed to find out...
#idsky #medsky
journals.plos.org/plosone/arti...
#idsky #medsky
journals.plos.org/plosone/arti...
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled stu...
Background Streptococcus pneumoniae (pneumococcus) and respiratory syncytial virus (RSV) are major causes of respiratory infections globally. Viral and bacterial co-infections are commonly observed in...
journals.plos.org
July 2, 2025 at 8:09 PM
RSV and pneumococcus demonstrate close interaction in epidemiological studies but which is 🐥 and which is 🥚. This study by our group is designed to find out...
#idsky #medsky
journals.plos.org/plosone/arti...
#idsky #medsky
journals.plos.org/plosone/arti...
Reposted by Josh Osowicki
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge.
Kitson, G., Byford, M., Cass, L. et al.
Infect Dis Ther (2025).
doi.org/10.1007/s401...
Kitson, G., Byford, M., Cass, L. et al.
Infect Dis Ther (2025).
doi.org/10.1007/s401...
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge - ...
Introduction Viral respiratory tract infections are of global concern, with an unmet need for a broad-spectrum antiviral prophylactic. HEX17, a multivalent carbohydrate-binding module, binds to sialic...
doi.org
July 2, 2025 at 8:51 AM
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge.
Kitson, G., Byford, M., Cass, L. et al.
Infect Dis Ther (2025).
doi.org/10.1007/s401...
Kitson, G., Byford, M., Cass, L. et al.
Infect Dis Ther (2025).
doi.org/10.1007/s401...
Reposted by Josh Osowicki
Come & work with me @benvyle.bsky.social @lshtm.bsky.social & @thelovetankcic.bsky.social Research Assistant with funded PhD within multidisciplinary project on Syphilis & STI control in the UK. Working with us to understand stakeholder & community perspectives on novel STI control strategies
Job Opportunity at LSHTM: Research Assistant
The London School of Hygiene & Tropical Medicine (LSHTM) is one of the world’s leading public health universities. Our mission is to improve health and health equity in the UK and worldwide; working i...
jobs.lshtm.ac.uk
June 24, 2025 at 3:27 PM
Come & work with me @benvyle.bsky.social @lshtm.bsky.social & @thelovetankcic.bsky.social Research Assistant with funded PhD within multidisciplinary project on Syphilis & STI control in the UK. Working with us to understand stakeholder & community perspectives on novel STI control strategies
Reposted by Josh Osowicki
Read the latest Journal of #Infection for the Phase-IIa trial and how it evaluates the safety and pharmacokinetics of high-dose, 10 weekly subcutaneous injections of penicillin (#SCIP) in young people with a history of acute rheumatic fever (#ARF) 👉 www.journalofinfecti...
June 22, 2025 at 9:16 AM
Read the latest Journal of #Infection for the Phase-IIa trial and how it evaluates the safety and pharmacokinetics of high-dose, 10 weekly subcutaneous injections of penicillin (#SCIP) in young people with a history of acute rheumatic fever (#ARF) 👉 www.journalofinfecti...
Reposted by Josh Osowicki
🄰🅆🄴🅂🄾🄼🄴
Stubbusch et al 𝘚𝘊𝘐𝘌𝘕𝘊𝘌
Bacteria 🦠 repurpose Type VI Secretion Systems based on environmental cues:
Nutrient-rich environments ➜ kill competitors
Under starvation ➜ lyse neighbors to scavenge their nutrients
Even “non-pathogens” shift from competition to predation as a survival strategy
Stubbusch et al 𝘚𝘊𝘐𝘌𝘕𝘊𝘌
Bacteria 🦠 repurpose Type VI Secretion Systems based on environmental cues:
Nutrient-rich environments ➜ kill competitors
Under starvation ➜ lyse neighbors to scavenge their nutrients
Even “non-pathogens” shift from competition to predation as a survival strategy
Antagonism as a foraging strategy in microbial communities
In natural habitats, nutrient availability limits bacterial growth. We discovered that bacteria can overcome this limitation by acquiring nutrients by lysing neighboring cells through contact-dependen...
www.science.org
June 14, 2025 at 4:37 AM
🄰🅆🄴🅂🄾🄼🄴
Stubbusch et al 𝘚𝘊𝘐𝘌𝘕𝘊𝘌
Bacteria 🦠 repurpose Type VI Secretion Systems based on environmental cues:
Nutrient-rich environments ➜ kill competitors
Under starvation ➜ lyse neighbors to scavenge their nutrients
Even “non-pathogens” shift from competition to predation as a survival strategy
Stubbusch et al 𝘚𝘊𝘐𝘌𝘕𝘊𝘌
Bacteria 🦠 repurpose Type VI Secretion Systems based on environmental cues:
Nutrient-rich environments ➜ kill competitors
Under starvation ➜ lyse neighbors to scavenge their nutrients
Even “non-pathogens” shift from competition to predation as a survival strategy
Reposted by Josh Osowicki
Dr O Xie has an entertaining talk on S. dys subsp eq [SDSE]
🐴 iSDSE has similar incidence and mortality v iGAS
🐎 Less genomic clustering in SDSE
🫏 Global dissemination iSDSE driven by stG62647-lineage
#LISSSD25 #clinmicro #idsky
🐴 iSDSE has similar incidence and mortality v iGAS
🐎 Less genomic clustering in SDSE
🫏 Global dissemination iSDSE driven by stG62647-lineage
#LISSSD25 #clinmicro #idsky
June 5, 2025 at 12:59 AM
Dr O Xie has an entertaining talk on S. dys subsp eq [SDSE]
🐴 iSDSE has similar incidence and mortality v iGAS
🐎 Less genomic clustering in SDSE
🫏 Global dissemination iSDSE driven by stG62647-lineage
#LISSSD25 #clinmicro #idsky
🐴 iSDSE has similar incidence and mortality v iGAS
🐎 Less genomic clustering in SDSE
🫏 Global dissemination iSDSE driven by stG62647-lineage
#LISSSD25 #clinmicro #idsky
Reposted by Josh Osowicki
Last of the #LISSSD25 presentations is Prof Victor Nizet imploring the community to think like streptococci in these times of authoritarianism USA anti-science
🍇 Evade host immunity (cont to do work)
🍇 Form biofilms (network)
🍇 Colonise diverse hosts (expand skill sets)
#strep #idsky
🍇 Evade host immunity (cont to do work)
🍇 Form biofilms (network)
🍇 Colonise diverse hosts (expand skill sets)
#strep #idsky
June 5, 2025 at 4:04 AM
Reposted by Josh Osowicki
I said no more #LISSSD25 posts but forgot a major highlight!
Most sessions started w/ a patient lived experience video, and you can see them all @ lisssd2025.org/patient-stories
Looking after patients during thier illnesses is v. stressful so it's great to hear their experiences when recovered.
Most sessions started w/ a patient lived experience video, and you can see them all @ lisssd2025.org/patient-stories
Looking after patients during thier illnesses is v. stressful so it's great to hear their experiences when recovered.
Patient Stories — LISSSD 2025
www.lisssd2025.org
June 5, 2025 at 7:33 AM
I said no more #LISSSD25 posts but forgot a major highlight!
Most sessions started w/ a patient lived experience video, and you can see them all @ lisssd2025.org/patient-stories
Looking after patients during thier illnesses is v. stressful so it's great to hear their experiences when recovered.
Most sessions started w/ a patient lived experience video, and you can see them all @ lisssd2025.org/patient-stories
Looking after patients during thier illnesses is v. stressful so it's great to hear their experiences when recovered.